Vermillion Exhibits OVA1 Ethnic Disparity Performance Poster at the American Association for Cancer Research (AACR) Annual Meeting

For link to the full press release click here
AUSTIN, Texas, April 2, 2019 — Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is being represented at the 2019 American Association for Cancer Research Annual Meeting with a poster entitled “Ethnic Disparity in Detection of Ovarian Malignancy.” The poster was authored by Dr. Charles Dunton, MD, Vermillion’s Global Medical Director and Dr. Herbert Fritsche, PhD, the Clinical Laboratory Director of ASPiRA LABS®.  The research presented in this poster highlights the superior diagnostic sensitivity of OVA1® versus ROMA® (CA125 + HE4) in African American women.
“This poster exhibit at AACR supports Vermillion’s commitment to innovative research as well as our mission to demonstrate ethnic disparity in pelvic mass ovarian risk assessment tools,” said Valerie Palmieri, President and CEO of Vermillion, Inc.  “As we continue with our publication pipeline, we believe that our FDA-cleared, guideline supported technology will demonstrate that OVA1® is vastly superior in assessing ovarian cancer risk in African American women as compared to the 38-year-old standard of care, CA125, as well as ROMA®. All women of every socioeconomic background should receive the best care possible and we are proud and excited to make that happen.”
The research presented in this poster demonstrates that current testing, CA-125 and ROMA® (HE4 and CA125), have lower sensitivities than OVA1® when tested on all ethnicities, especially in African American women.  “As a practicing physician for 30 years, I believe the inferior sensitivity of CA-125 and ROMA®, especially in African American women is very significant and needs to be recognized” stated Dr. Charles Dunton MD, Gynecologic Oncologist and Global Medical Director, Vermillion, Inc.
OVA1® is FDA-cleared, American College of Obstetrician and Gynecologist (ACOG) endorsed and has the highest risk detection rate for all ages, ethnicities, stages and all types of ovarian cancer.
The AACR annual meeting is being held at the Georgia World Congress Center in Atlanta. The poster exhibit at AACR will be displayed for review on Tuesday April 2nd,from 8:00 a.m. to 12:00 p.m. Vermillion, Inc. is also exhibiting at the annual meeting at booth 5110.
About Vermillion 
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for OVERA®, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. In the fourth quarter of 2018, the company launched its new generation of technology OVA1+® , which is designed to improve accuracy and reduce false positives by nearly 40% by leveraging the strengths of OVA1’s sensitivity and OVERA’s specificity. Vermillion’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Forward-Looking Statement
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements.  These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in Vermillion’s business, including those described in the section entitled “Risk Factors” in Vermillion’s Annual Report on Form 10-K for the year ended December 31, 2018.  The events and circumstances reflected in Vermillion’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
Investor Relations Contact: 
Ashley R. Robinson
LifeSci Advisors LLC
Tel: (646) 535-7742
[email protected]